• Ave. 31 No. 15802 between 158 y 190, Cubanacán, Playa, Havana. C.P. 11600, P.O. Box 6162
  • webmaster@cigb.edu.cu
  • (53) 7-2504101; (53) 7-2716022

Noticias

Speech by the Director General at the Central Ceremony for the 40th Anniversary of the Center for Genetic Engineering and Biotechnology
0 mf
Nasalferon: health registration for the prophylaxis and treatment of viral respiratory infections
0 Nayade Beltran Matos
Jusvinza represents a very important hope for the health of the Cuban people
0 mf
We continue to investigate the rationale behind Jusvinza’s mechanisms of action
0 mf
Results from phase 2 clinical studies for the treatment of people with arthritis secondary to Chikungunya virus infection, in the post-acute and chronic stages
0 mf
Designed as an immunomodulator, but without inducing immunosuppression: the origins and advances of Jusvinza
0 mf
Jusvinza, an innovative drug for the treatment of inflammation
0 mf
A biochemist, a peptide, and recognition for an entire generation
0 mf
MSc. Karen Urrutia Pérez
Young scientist at CIGB: vocation, rigor, and commitment
0 mf
Member of the World Academy of Sciences (TWAS)
0 mf
Main contributions and results of agricultural biotechnology
0 mf
Jusvinza: innovative therapeutic product for autoimmune diseases
0 mf
Interview to Dr.C. Julio Raul in the News Program Buenos Días
0 mf
Cuba and Spain in Triangular Cooperation Initiative supported by the EU
0 mf
Bets from science for a higher agricultural yield
0 mf
Purity and efficacy of Mambisa, the first anti-covid nasal vaccine (Part II)
0 mf
Purity and efficacy of Mambisa, the first anti-covid nasal vaccine (Part I)
0 mf
Mambisa: nasally-administered COVID-19 vaccine candidate
0 mf
Abdala effectiveness
0 mf
Cecmed issued a positive dictamen in favor of a booster dose of Abdala
0 mf
Cecmed approved the clinical study of a booster dose with Mambisa nasal-applied COVID-19 vaccine candidate
0 mf
Abdala showed high levels of seroconversion greater than 98% in pediatric population
0 mf
Cuban scientist receives Latin American Women in Chemistry Award 2021
0 mf
Cuban researchers elected as new members of the World Academy of Sciences (TWAS)
0 mf
Abdala already has an Emergency Use Authorization in three countries
0 mf
Young people: main protagonists in the productive escalation of Jusvinza
0 mf
The Abdala vaccine is 90% effective in critically ill patients, even with circulation of the Delta strain
0 mf
In Cuba, 30 million doses of the Abdala vaccine have been manufactured
0 mf
Vietnam and Cuba strengthen ties in the field of biotechnology
0 mf
To WHO/PAHO, Cuba presents results in the development of anti-COVID-19 vaccines
0 ga
Cuba presents the results of its covid-19 vaccines to the WHO
0 mf
International certification of Heberbiovac HB®, recombinant vaccine against Hepatitis B
0
Abdala vaccine: 100% efficacy against severe disease and death in its phase III trial
0
“Ismaelillo” Pediatric Clinical Trial with Abdala
0
Second clinical trial in convalescent covid-19 begins in Cuba
0